Systemic viral interleukin-10 gene delivery prevents cartilage invasion by human rheumatoid synovial tissue engrafted in SCID mice

被引:0
|
作者
Jorgensen, C [1 ]
Apparailly, F
Canovas, F
Verwaerde, C
Auriault, C
Jacquet, C
Sany, J
机构
[1] Hop Lapeyronie, Serv Immunorhumatol, Montpellier 5, France
[2] INSERM, Montpellier, France
[3] Inst Pasteur, F-59019 Lille, France
来源
ARTHRITIS AND RHEUMATISM | 1999年 / 42卷 / 04期
关键词
D O I
10.1002/1529-0131(199904)42:4<678::AID-ANR10>3.0.CO;2-S
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To assess the effects of viral interleukin-10 (vIL-10) gene delivery on human rheumatoid synovial tissue. Methods. SCID mice were engrafted subcutaneously with human rheumatoid synovial tissue and homologous cartilage before systemic injection of 109 plaque-forming units of type 5 E1a E1b-deficient nonreplicative adenovirus vector containing the vIL-10 gene under control of the cytomegalovirus promoter (AdvIL-10; n = 10) or a control gene (AdvIL-10mut; n = 7). Three weeks later, the graft was removed for histologic analysis of cartilage invasion by synovial tissue. The number of CD3-positive mononuclear cells was assessed in the synovial tissue by immunohistology. Messenger RNA (mRNA) expression of matrix metalloproteinase 3 (MMP-3), tissue inhibitor of metalloproteinases 1 (TIMP-1), and proinflammatory cytokines was determined by polymerase chain reaction. Results. Systemic vIL-10 gene transfer resulted in high sustained production of vIL-10 protein in SCID mouse sera (mean +/- SD 25 +/- 5 ng/ml on day 40 post vector injection). Moreover, vIL-10 mRNA expression was detected in the synovial tissue 3 weeks after intravenous injection of AdvIL-10, reflecting the gene transfer in the human graft. In animals treated with AdvIL-10, cartilage invasion by rheumatoid synovial tissue was significantly inhibited compared with the control vector (mean +/- SD histologic score 2.5 +/- 0.52 versus 0.75 +/- 0.8; P < 0.0001). The number of T cells infiltrating the synovium and perichondral resorption in the animals treated with AdvIL-10 gene were not significantly modified relative to the control vector. In animals treated with AdvIL-10, the MMP3-TIMP-1 balance was partially restored, independent of the effect on mRNA expression of tumor necrosis factor alpha, IL-1, IL-6, or IL-8. Conclusion. Systemic vIL-10 gene transfer prevented cartilage invasion by synovial tissue engrafted in SCID mice. This model offers the opportunity to study the biologic effects of gene transfer in vivo in rheumatoid synovium.
引用
收藏
页码:678 / 685
页数:8
相关论文
共 50 条
  • [31] Systemic delivery of interleukin 10 by intramuscular injection of expression plasmid DNA prevents autoimmune diabetes in nonobese diabetic mice
    Nitta, Y
    Tashiro, F
    Tokui, M
    Shimada, A
    Takei, I
    Tabayashi, K
    Miyazaki, J
    HUMAN GENE THERAPY, 1998, 9 (12) : 1701 - 1707
  • [32] Interleukin-10 gene therapy utilizing adeno-associated virus vectors prevents type 1 diabetes in NOD mice
    Goudy, K
    Ellis, T
    Ottendorfer, E
    Song, SH
    Wasserfall, C
    Flotte, T
    Atkinson, M
    DIABETES, 2001, 50 : A33 - A33
  • [33] Hydrodynamics-based delivery of the viral interleukin-10 gene suppresses experimental crescentic glomerulonephritis in Wistar-Kyoto rats
    Higuchi, N
    Maruyama, H
    Kuroda, T
    Kameda, S
    Iino, N
    Kawachi, H
    Nishikawa, Y
    Hanawa, H
    Tahara, H
    Miyazaki, J
    Gejyo, F
    GENE THERAPY, 2003, 10 (16) : 1297 - 1310
  • [34] QUANTITATIVE-EVALUATION OF INTERLEUKIN-10 (IL-10) GENE-EXPRESSION IN SYNOVIAL TISSUE IN OSTEOARTHRITIS (OA) AND IN INFLAMMATORY JOINT DISEASES (INFLJD)
    BREBAN, M
    ROPARS, A
    AYRAL, X
    DOUGADOS, M
    SIMONNET, J
    AMOR, B
    FRADELIZI, D
    ARTHRITIS AND RHEUMATISM, 1995, 38 (09): : 1200 - 1200
  • [35] Interleukin-10 plasmid delivery by polymeric nanocarrier shows efficient and safe tissue repair in acute muscle damage models in mice
    Xie, Xiaodong
    Jiang, Jinhong
    Liu, Xiangsheng
    Cao, Yuhong
    Li, Jiulong
    Xia, Tian
    Meng, Huan
    NANO TODAY, 2022, 46
  • [36] Gene therapy of experimental autoimmune thyroiditis mice by in vivo administration of plasmid DNA coding for human interleukin-10
    Zhang, ZL
    Lin, B
    Yu, LY
    Shen, SX
    Zhu, LH
    Wang, WP
    Guo, LH
    ACTA PHARMACOLOGICA SINICA, 2003, 24 (09) : 885 - 890
  • [37] Effects of spinal non-viral interleukin-10 gene therapy formulated with D-mannose in neuropathic interleukin-10 deficient mice: Behavioral characterization, mRNA and protein analysis in pain relevant tissues
    Vanderwall, Arden G.
    Noor, Shahani
    Sun, Melody S.
    Sanchez, Jacob E.
    Yang, Xuexian O.
    Jantzie, Lauren L.
    Mellios, Nikolaos
    Milligan, Erin D.
    BRAIN BEHAVIOR AND IMMUNITY, 2018, 69 : 91 - 112
  • [38] Airway-directed gene transfer of interleukin-10 using recombinant Sendai virus effectively prevents posttransplant fibrous airway obliteration in mice
    Shoji, F
    Yonemitsu, Y
    Okano, S
    Yoshino, I
    Nakagawa, K
    Nakashima, Y
    Hasegawa, M
    Sugimachi, K
    Sueishi, K
    GENE THERAPY, 2003, 10 (03) : 213 - 218
  • [39] Delivery of interleukin-10 via injectable hydrogels improves renal outcomes and reduces systemic inflammation following ischemic acute kidney injury in mice
    Soranno, Danielle E.
    Rodell, Christopher B.
    Altmann, Christopher
    Duplantis, Jane
    Andres-Hernando, Ana
    Burdick, Jason A.
    Faubel, Sarah
    AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2016, 311 (02) : F362 - F372
  • [40] Adenovirus-mediated gene delivery of interleukin-10, but not transforming growth factor β, ameliorates the induction of Graves' hyperthyroidism in BALB/c mice
    Saitoh, O
    Mizutori, Y
    Takamura, N
    Yamasaki, H
    Kita, A
    Kuwahara, H
    Nagayama, Y
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2005, 141 (03): : 405 - 411